Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 688 • 2019 ACR/ARP Annual Meeting
Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
Rosa Maria Serrano¹, Guillermo Pons-Estel ², Manuel Ugarte-Gil ³, Guillermina B Harvey ⁴, Daniel Wojdyla ⁵, Veronica Saurit ⁶, Enrique Soriano ⁷, Eloisa Bonfa ⁸, Loreto Massardo ⁹, Mario Cardiel ¹⁰, Rosana Quintana ¹, Graciela Alarcón ¹¹ and Bernardo A. Pons-Estel ¹², ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño,Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR),Grupo Oroño, Rosario, Rosario, Argentina, ³Universidad Científica del Sur, Lima, Peru, ⁴GLADEL, Rosario, Argentina, ⁵GLADEL Consultant, Rosario, Argentina, ⁶Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina, ⁸Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁹Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia. Universidad San Sebastián, Santiago, Chile., Santiago, Chile, ¹⁰Centro de Investigación Clínica de Morelia, SC, Morelia, México., Morelia, Mexico, ¹¹University of Alabama at Birmingham, Birmingham, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina
Background/Purpose: Diagnosis and classification of patients as having systemic lupus erythematosus (SLE) is critical in daily clinical practice as well as for clinical trials and…
Abstract Number: 963 • 2019 ACR/ARP Annual Meeting
Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNα and TNFRII in ANA+ Healthy Individuals
Aleksandra Bylinska¹, Samantha Slight-Webb ¹, Miles Smith ², Susan R. Macwana ¹, Nicolas Dominguez ¹, Eliza F. Chakravarty ³, Joan T. Merrill ⁴, Judith James ³ and Joel Guthridge ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Loss of systemic self-tolerance leading to anti-nuclear autoantibody (ANAs) by B cells is a hallmark of SLE. However, up to 20% of healthy female…
Abstract Number: 1110 • 2019 ACR/ARP Annual Meeting
Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study
Trevor Faith¹, Jihad Obeid ¹, Kit Simpson ¹ and Diane Kamen ², ¹Medical University of South Carolina, Charleston, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Participating in clinical research can be burdensome for subjects due to time and travel barriers, particularly among underserved, rural, and/or chronic disease bearing populations…
Abstract Number: 1573 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna Gladman ², Jiandong Su ¹, Vernon Farewell ³, Jorge Sanchez-Guerrero ⁴, Juanita Romero-Diaz ⁵, Sang-Cheol Bae ⁶, Paul Fortin ⁷, Ola Nived ⁸, Ann E Clarke ⁹, Sasha Bernatsky ¹⁰, Caroline Gordon ¹¹, John Hanly ¹², Daniel J Wallace ¹³, David A Isenberg ¹⁴, Anisur Rahman ¹⁵, Joan Merrill ¹⁶, Ellen M Ginzler ¹⁷, Graciela Alarcon ¹⁸, Michelle Petri ¹⁹, Ian Bruce ²⁰, Munther A Khamashta ²¹, Cynthia Aranow ²², Susan Manzi ²³, MA Dooley ²⁴, Rosalind Ramsey-Goldman ²⁵, Andreas Jönsen ⁸, Kristjan Steinsson ²⁶, Asad Zoma ²⁷, Guillermo Ruiz-Irastorza ²⁸, S Sam Lim ²⁹, Kenneth C Kalunian ³⁰, Murat Inanc ³¹, Ronald van Vollenhoven ³², Manuel Ramos ³³, Diane Kamen ³⁴, Soren Jacobsen ³⁵, Christine Peschken ³⁶, Anca Askanase ³⁷ and Thomas Stoll ³⁸, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University of Cambridge, Cambridge, United Kingdom, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁸Lund University, Lund, Sweden, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹University of Birmingham, Birmingham, United Kingdom, ¹²Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ¹³Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹⁴Centre for Rheumatology, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁸The University of Alabama at Birmingham, Birmingham, AL, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²¹King's College London School of Medicine, London, United Kingdom, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Allegheny Health Network, Pittsburg, PA, ²⁴UnC Kidney Centre, Chapel Hill, NC, ²⁵Northwestern University, Chicago, IL, ²⁶Landspitali, University Hospital, Reykjavik, Iceland, ²⁷Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ²⁸Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Bizkaia, Spain, ²⁹Emory University, Atlanta, GA, ³⁰UC San Diego School of Medicine, LaJolla, CA, ³¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³³Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶University of Manitoba, Winnipeg, Canada, ³⁷Columbia University Medical Center, New York, NY, ³⁸University of Glasgow, Kilbride, Scotland, United Kingdom
Background/Purpose: The prevalence of atherosclerotic vascular events (AVE) in published literature of an inception cohort with SLE is 10%. We aimed to investigate the accrual…
Abstract Number: 1616 • 2019 ACR/ARP Annual Meeting
Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim is to investigate the association between the…
Abstract Number: 1827 • 2019 ACR/ARP Annual Meeting
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Stanley Moore ¹, Hsin-Hsuan Juo ¹, Christoffer Nielsen ², Helena Tyden ³, Anders Bengtsson ³ and Christian Lood¹, ¹University of Washington, Seattle, ²Statens Serum Institut, Copenhagen, Denmark, ³Lund University, Lund, Sweden
Background/Purpose: Neutrophil activation, including formation of neutrophil extracellular traps (NETs), is essential in host defense. However, NET formation has also been linked to inflammation and…
Abstract Number: 2035 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
Shunichi Shiozawa¹, Ken Tsumiyama ¹, Yumi Miyazaki ², Keiichi Sakurai ³, Takahiko Horiuchi ⁴, Motohiro Oribe ⁵, Takashi Yamane ⁶, Hidetoshi Kagawa ⁷ and Kazuko Shiozawa ⁸, ¹Institute for Rheumatic Diseases, Ashiya, Japan, ²Kyushu University Beppu Hospital, Tokyo, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁵Oribe Rheumatology Clinic, Oita, Japan, ⁶Department of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Japan, ⁷Rheumatology, Red Cross Society Himeji Hospital, Himeji, Japan, ⁸Rheumatic Diseases Center, Hyogo Prefectural Kakogawa Medical Center, Ashiya, Japan
Background/Purpose: We previously found in reproducible experiments in which the mice not prone to autoimmune disease were immunized repeatedly with antigen that overstimulation of CD4…
Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Stephen McDonald¹, Eoghan McCarthy ², Aysun Aksoy ³, Ben Parker ⁴ and Ian Bruce ⁵, ¹University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, ²Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ⁴University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
Abstract Number: 2554 • 2019 ACR/ARP Annual Meeting
Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Low Disease Activity State (LLDAS) has been associated with favourable outcomes in systemic lupus erythematosus (SLE). However, the complexity of its defining criteria…
Abstract Number: 2783 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous
Maximlian Konig¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has a primary role in the treatment of systemic lupus erythematous (SLE). Beyond its pleiotropic immunomodulatory effects on TLR…
Abstract Number: 69 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Ralph Budd¹, Karen Fortner ¹, Luz Blanco ², Mariana Kaplan ³, Andras Perl ⁴, Iwona Busliewicz ⁵, Greg MacPherson ⁶ and Mike Murphy ⁷, ¹The University of Vermont Larner College of Medicine, Burlington, VT, ²NIH NIAMS, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, ⁴SUNY Upstate Medical University, Syracuse, NY, ⁵Upstate Medical Center, Syracuse, NY, ⁶MitoQ, Aukland, New Zealand, ⁷Wellcome MRC Mitochondrial Biology Unit, Cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a type I Interferon (IFN-I) gene signature in peripheral blood lymphocytes (PBL), which contain enlarged mitochondria and…
Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…
Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Cristina Arriens¹, Dylan Forciea ², Judith James ¹ and Joan T. Merrill ³, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oseberg, Oklahoma City, OK, ³Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Prathima Anandi ¹, Alyson Dickson ², Vivian Kawai ², C. Michael Stein ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].